Fornander T, Rutqvist L E, Cedermark B, Glas U, Mattsson A, Silfverswärd C, Skoog L, Somell A, Theve T, Wilking N
Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Lancet. 1989 Jan 21;1(8630):117-20. doi: 10.1016/s0140-6736(89)91141-0.
The frequency of new primary cancers was studied in 1846 postmenopausal patients included in a randomised trial of tamoxifen as an adjunct to primary surgery for early breast cancer. The median follow-up was 4.5 years (range 0.5-10.5 years). The number of new cancers in the tamoxifen group (n = 57) did not differ significantly from that in the control group (n = 70). However, in tamoxifen patients second breast cancers occurred less often and endometrial cancer occurred more often than in the controls. The increase in endometrial cancers was probably related to the agonistic oestrogenic effects of tamoxifen and was most pronounced in those treated for over 2 years.
在一项他莫昔芬作为早期乳腺癌原发手术辅助治疗的随机试验纳入的1846例绝经后患者中，对新发原发性癌症的发生率进行了研究。中位随访时间为4.5年（范围0.5 - 10.5年）。他莫昔芬组（n = 57）的新发癌症数量与对照组（n = 70）相比无显著差异。然而，与对照组相比，他莫昔芬治疗的患者中，对侧乳腺癌的发生率较低，而子宫内膜癌的发生率较高。子宫内膜癌的增加可能与他莫昔芬的雌激素激动作用有关，在治疗超过2年的患者中最为明显。
